Table 2.
Current medication, extraarticular manifestations, and comorbidities of enrolled patients
| Characteristics | All patients with DAS28 <2.6 at first year follow up (n=680) | Patients with DAS28 <2.6 and VAS-pain ≥4 (n=146) | Patients with DAS28 <2.6 and VAS-pain <4 (n=534) |
p-value |
|---|---|---|---|---|
| Previous treatment | ||||
| Prior use of methotrexate | 579 (85.1) | 117 (80.1) | 462 (86.5) | 0.055 |
| Prior use of bDMARDs or tsDMARDs | 159 (23.4) | 45 (30.8) | 114 (21.3) | 0.017 |
| Current treatment | ||||
| bDMARDs or tsDMARDs | 0.001 | |||
| Anti-TNF | 270 (39.7) | 53 (36.3) | 217 (40.6) | |
| Rituximab | 3 (0.4) | 0 (0.0) | 3 (0.6) | |
| Tocilizumab | 294 (43.2) | 82 (56.2) | 212 (39.7) | |
| Abatacept | 63 (22.5) | 7 (4.8) | 56 (10.5) | |
| JAKis | 50 (7.4) | 4 (2.7) | 46 (8.6) | |
| Corticosteroid use | 444 (65.3) | 116 (79.5) | 328 (61.4) | <0.001 |
| Concomitant cDMARDs use | 598 (87.9) | 126 (86.3) | 472 (88.4) | 0.492 |
| Comorbidities* | ||||
| Cardiovascular disorders | 296 (43.5) | 72 (49.3) | 224 (41.9) | 0.112 |
| Neurological disorders | 16 (2.4) | 8 (5.5) | 8 (1.5) | 0.005 |
| Pulmonary disorders | 31 (4.6) | 5 (3.4) | 26 (4.9) | 0.458 |
| Endocrine disorders | 263 (38.7) | 67 (45.9) | 196 (36.7) | 0.043 |
| Renal disorders | 6 (0.9) | 4 (2.7) | 2 (0.4) | 0.021 |
| Gastrointestinal disorders | 23 (3.4) | 5 (3.4) | 18 (3.4) | 0.975 |
| Viral/infectious disorders | 28 (4.1) | 7 (4.8) | 21 (3.9) | 0.642 |
| Drug abuse/dependence | 1 (0.1) | 0 (0.0) | 1 (0.2) | 0.999 |
| Mental illness | 14 (2.1) | 6 (4.1) | 8 (1.5) | 0.049 |
| Hematology & Oncology | 152 (22.4) | 33 (22.6) | 119 (22.3) | 0.935 |
Data are presented as number (%). DAS28: disease activity score of 28 joints, VAS: visual analog scale, bDMARDs: biologic disease modifying anti-rheumatic drugs, tsDMARDs: targeted synthetic DMARDs, TNF: tumor necrosis factor, JAKis: janus kinase inhibitors, cDMARDs: conventional DMARDs. *These data were assessed by chi-square test or Fisher exact test due to low frequency.